SS-31, also known as elamipretide and by its original research designation as a Szeto-Schiller peptide, is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. Unlike conventional cell-permeable peptides that distribute broadly throughout the cytosol, SS-31 selectively concentrates within the inner mitochondrial membrane, reportedly reaching intramitochondrial concentrations several thousand-fold higher than surrounding cytoplasmic levels. This selective accumulation is driven by an alternating aromatic-cationic structural motif combined with the large negative membrane potential characteristic of respiring mitochondria. Within laboratory research, ss 31 peptide is used extensively as a tool compound for studying mitochondrial bioenergetics, cardiolipin biochemistry, and inner-membrane oxidative stress pathways in cell and animal models.
What Is SS-31 Peptide?
SS-31 is a four-amino-acid peptide consisting of D-arginine, 2′,6′-dimethyltyrosine (Dmt), lysine and phenylalanine amide, first developed by Hazel Szeto and Peter Schiller during research into opioid receptor pharmacology, before its distinct mitochondria-targeting properties were characterised. Structurally, SS-31 belongs to a broader class of Szeto-Schiller peptides defined by an alternating cationic and aromatic amino acid arrangement, a motif responsible for both the compound’s cell permeability across a wide range of cell types and its subsequent selective concentration within mitochondria specifically.
This alternating aromatic-cationic structural pattern is central to understanding SS-31’s targeting mechanism, which is fundamentally different from most mitochondria-directed compounds. Many mitochondria-targeted molecules rely on conjugation to a lipophilic cation, such as triphenylphosphonium, to drive accumulation across the mitochondrial membrane potential. SS-31, by contrast, achieves its selective mitochondrial concentration through the intrinsic properties of its own amino acid sequence, without requiring a separate targeting moiety, a distinction that has been described in the literature as an independent mitochondrial targeting mechanism relative to conjugate-based approaches.
Cardiolipin binding affinity represents the second defining structural property of SS-31. Cardiolipin is an anionic phospholipid with an unusual dimeric structure comprising a two-phosphate headgroup and four acyl chains, and it is found almost exclusively within the inner mitochondrial membrane, where it constitutes roughly 10 to 20 mol percent of total membrane lipids. Biophysical research using model and isolated mitochondrial membranes has demonstrated that SS-31, as a polybasic peptide, partitions into the membrane interfacial region with an affinity and lipid-binding density directly related to the local surface charge, meaning the peptide preferentially accumulates at cardiolipin-rich regions of the inner membrane due to electrostatic interaction between its cationic residues and the anionic phospholipid headgroups.
Blood-brain barrier penetration capability has also been reported for SS-31 in preclinical research, a property attributed to its small size and specific physicochemical characteristics, and this has supported its use as a research tool in central nervous system mitochondrial dysfunction models, including neurodegenerative and ophthalmic research contexts, in addition to its more extensively documented use in renal and cardiac tissue research.
Mechanism of Action
The central mechanism attributed to SS-31 in the published literature is its interaction with cardiolipin at the inner mitochondrial membrane, and this interaction has been characterised as driving several interrelated downstream effects rather than a single isolated action. Biophysical research using a polarity-sensitive fluorescent analogue of SS-31 has demonstrated that the peptide binds cardiolipin with high affinity, and that this SS-31-cardiolipin complex inhibits the peroxidase activity of cytochrome c, an enzymatic activity that is normally suppressed under healthy mitochondrial conditions but that becomes pathologically activated when cytochrome c interacts with peroxidised cardiolipin during oxidative stress. By protecting the heme iron of cytochrome c from this interaction, SS-31 has been reported to prevent cardiolipin peroxidation, a chain of lipid oxidation events that otherwise contributes to mitochondrial membrane damage during conditions such as ischemia-reperfusion injury.
Structural optimisation of mitochondrial cristae, the folded inner-membrane structures that house the electron transport chain complexes, has been documented as a further consequence of SS-31’s cardiolipin interaction. Electron microscopy studies examining renal tissue following induced ischemia have reported that SS-31 treatment preserved the integrity of mitochondrial cristae architecture and prevented mitochondrial swelling during the ischemic period, findings attributed to the peptide’s stabilising interaction with cardiolipin, which is itself required for proper cristae formation and for the organisation of respiratory complexes within the inner membrane.
This structural stabilisation has direct implications for electron transport chain efficiency. Because cardiolipin is required for the assembly and stability of respiratory chain supercomplexes, SS-31’s cardiolipin-stabilising activity has been proposed to reduce electron leak at its source within the electron transport chain, rather than acting solely as a downstream scavenger of reactive oxygen species (ROS) already generated. This distinguishes SS-31 mechanistically from conventional antioxidant compounds, which act throughout the cell after ROS have already formed; SS-31’s concentrated inner-membrane localisation and cardiolipin-stabilising activity instead target the structural source of excess electron leak associated with mitochondrial dysfunction.
ATP synthesis modulation has been documented as a functional consequence of these combined structural effects. Research using rat models of renal ischemia-reperfusion injury has reported that SS-31 treatment accelerated the recovery of ATP levels following reperfusion, with prompt ATP recovery in turn supporting rapid repair of ATP-dependent cellular processes, including restoration of the actin cytoskeleton and tubular cell polarity, alongside reduced apoptosis and necrosis in affected tissue.
Mitochondrial ROS reduction has historically been proposed as SS-31’s primary mechanism, based on the free-radical-scavenging capacity of its dimethyltyrosine residue, which can interact with oxygen radicals to form comparatively unreactive tyrosine radicals that couple together into di-tyrosine. However, more recent mechanistic research has questioned whether direct antioxidant scavenging is SS-31’s primary mode of action, noting that such scavenging would not occur catalytically and that related Szeto-Schiller peptide variants lacking a radical-scavenging side chain, such as SS-20, have also demonstrated efficacy in preclinical studies. This has led researchers to conclude that cardiolipin-binding and membrane-electrostatic effects, rather than direct radical scavenging alone, likely represent the primary mechanism underlying SS-31’s broader research profile, with ROS reduction understood as a downstream consequence of improved electron transport chain organisation rather than the compound’s sole or primary mode of action.
What the Research Shows
Foundational mechanistic research characterising SS-31’s interaction with cardiolipin used a polarity-sensitive fluorescent analogue of the peptide to demonstrate high-affinity cardiolipin binding, reporting that the SS-31-cardiolipin complex inhibited cytochrome c peroxidase activity and protected cristae membranes during renal ischemia in a rat model, with pretreated animals showing prevention of mitochondrial swelling and prompt post-reperfusion ATP recovery linked to restoration of the actin cytoskeleton and tubular cell polarity (SS-31 cardiolipin re-energisation study).
An earlier study established the functional renal protective effect underlying this mechanism, reporting that subcutaneous SS-31 administration in a rat model of bilateral renal ischemia-reperfusion injury protected mitochondrial structure and respiration during early reperfusion, accelerated ATP recovery, reduced tubular cell apoptosis and necrosis, and reduced ischemia-reperfusion-mediated oxidative stress and inflammatory response, with significant differences reported across all measured biomarkers relative to saline-treated controls (SS-31 ischemic kidney injury study).
More recent biophysical research has extended this mechanistic picture using computational and biophysical approaches to characterise how SS-31 interacts with lipid bilayers, reporting that the peptide partitions into the membrane interfacial region with an affinity and lipid-binding density directly related to local surface charge, and that SS-31 measurably alters lipid bilayer electrostatic properties as a component of its overall mechanism of action, findings that have informed ongoing research into whether membrane-electrostatic effects, rather than direct antioxidant activity alone, represent the primary basis for the peptide’s research profile (SS-31 membrane electrostatics study).
Neurodegenerative research applications have also been documented, with SS-31 studied as a potential neuroprotective compound for retinal ganglion cells in preclinical glaucoma research models, reflecting the peptide’s reported blood-brain barrier penetration and broader relevance to central nervous system mitochondrial dysfunction research. Age-related mitochondrial dysfunction research has separately reported that SS-31 rapidly reverses age-associated declines in mitochondrial bioenergetic function and improves skeletal muscle performance measures in aged rodent models, findings that have contributed to research interest in SS-31 as a tool compound for studying mitochondrial contributions to age-related physiological decline across multiple tissue types, including cardiac, renal and skeletal muscle research models.
Research Applications
Within laboratory settings, SS-31 research peptide is used across several established mitochondrial bioenergetics research contexts. Isolated mitochondrial respirometry assays represent a core application, in which researchers use techniques such as Clark-type oxygen electrode measurement or high-resolution respirometry to characterise electron transport chain function and oxidative phosphorylation efficiency in isolated mitochondrial preparations exposed to SS-31, often under conditions of induced oxidative or ischemic stress designed to model mitochondrial dysfunction. Cardiolipin oxidation models constitute a further significant research application, in which researchers use lipidomic or spectrophotometric techniques to quantify cardiolipin peroxidation status in mitochondrial membrane preparations, directly examining the cardiolipin-protective mechanism central to SS-31’s proposed mode of action.
Intracellular ATP kinetics studies are used to characterise the time course of ATP recovery following induced metabolic stress, building directly on the renal ischemia-reperfusion research described above, and typically employ luciferase-based ATP quantification assays in cell culture or tissue homogenate preparations to track bioenergetic recovery following SS-31 exposure. Microvascular endothelial survival protocols represent a further research context, in which researchers examine endothelial cell viability and mitochondrial function under conditions of oxidative or hypoxic stress, relevant to broader cardiovascular and renal microvascular research applications of the compound. When selecting a certified SS-31 research peptide for isolated mitochondrial respirometry or cellular energy studies, researchers should confirm the exact tetrapeptide sequence and purity documentation supplied, since the specific D-arginine and dimethyltyrosine residues are central to reproducing the cardiolipin-binding and membrane-electrostatic effects reported in the primary literature.
Comparative pharmacology work has also examined SS-31 alongside related Szeto-Schiller peptide variants, including SS-20, which lacks the radical-scavenging dimethyltyrosine side chain, allowing researchers to isolate the relative contributions of direct antioxidant scavenging versus cardiolipin-binding and membrane-stabilising effects within this peptide class.
Purity, Analytical Verification, Storage and Handling
Research-grade SS-31 should be accompanied by a certificate of analysis confirming purity by HPLC, typically at or above 98 percent, together with mass spectrometry verification confirming the correct tetrapeptide sequence, including the D-arginine stereochemistry and dimethyltyrosine modification that are central to the compound’s mitochondrial targeting and cardiolipin-binding properties. Because SS-31’s biological activity depends on precise structural features, including its D-amino acid configuration and specific aromatic-cationic spacing, analytical verification of stereochemistry as well as sequence is particularly relevant to reproducing published bioenergetics findings. When evaluating high-purity ss 31 peptide for mitochondrial bioenergetics assays, UK research laboratories must ensure each batch is validated with this documentation rather than relying on a generic product listing.
Lyophilised SS-31 should be stored at -20°C, protected from light and moisture, in order to preserve peptide integrity and stereochemical configuration prior to reconstitution. Reconstitution should be carried out using sterile buffer solutions appropriate to the intended assay, with researchers following supplier-specific guidance to ensure consistency with published experimental protocols, since buffer pH and ionic strength can influence the peptide’s electrostatic interaction with cardiolipin-containing membranes in downstream assays. Photo- and thermal-protection protocols are particularly relevant for SS-31 given its aromatic dimethyltyrosine residue, which can be susceptible to oxidative degradation under prolonged light exposure or elevated temperature; reconstituted solutions should therefore be stored in amber or foil-wrapped vials, refrigerated at 2-8°C, used within the supplier’s stated stability window, and protected from repeated freeze-thaw cycling through appropriate aliquoting.
Frequently Asked Questions
How does SS-31 achieve selective mitochondrial targeting without a separate targeting moiety?
SS-31’s alternating aromatic-cationic amino acid sequence enables both broad cell permeability and subsequent selective concentration within mitochondria, driven by the large negative membrane potential of respiring mitochondria. This distinguishes it from other mitochondria-targeted compounds that require conjugation to a separate lipophilic cation carrier, such as triphenylphosphonium, to achieve comparable accumulation.
What role does cardiolipin play in SS-31’s mechanism of action?
Cardiolipin is an anionic phospholipid concentrated in the inner mitochondrial membrane, and SS-31 binds it with high affinity through electrostatic interaction. This binding has been reported to stabilise cardiolipin-cytochrome c interactions, inhibit pathological cytochrome c peroxidase activity, and help preserve mitochondrial cristae architecture during oxidative or ischemic stress in preclinical models.
Is SS-31 primarily a direct antioxidant or does it act through a different mechanism?
While SS-31’s dimethyltyrosine residue can scavenge free radicals, more recent research has questioned whether this is its primary mechanism, noting that related Szeto-Schiller variants lacking this radical-scavenging side chain remain effective in preclinical studies. Current research points to cardiolipin-binding and membrane-electrostatic effects as the more likely primary mode of action.
How should research-grade SS-31 be verified before use in a bioenergetics assay?
Researchers should request a batch-specific certificate of analysis confirming HPLC purity of 98 percent or higher and mass spectrometry confirmation of the correct tetrapeptide sequence and D-arginine stereochemistry, since precise structural features, not just amino acid composition, are directly relevant to reproducing cardiolipin-binding and mitochondrial respirometry findings reported in the literature.
SS-31 peptide, as supplied by Peptides Lab UK and comparable UK research suppliers, is intended strictly for in-vitro and animal-model laboratory research. It is not licensed or intended for human or veterinary use, and nothing in this article should be interpreted as guidance for personal administration.
